GENEMEDICS APP

GENEMEDICS NUTRITION

GW0742

Author: Dr. George Shanlikian, M.D.  |   Last Updated: May 21st, 2025

Share This Page

Book a Free Consultation

Potential Health Benefits of GW0742

  • Promotes muscle regeneration and increases exercise endurance [1-10]
  • Helps lose weight [1] [11-16]
  • Lowers the risk of heart disease [13] [17-21]
  • Accelerates wound healing [22-23]
  • Boosts brain power [24-35]
  • Lowers blood pressure [36-38]
  • Improves blood sugar levels and treats symptoms of diabetes [39-46]
  • Treats lung injuries [20] [47-50]
  • Improves eye health [51-52]

What is GW0742?

GW0742 is a selective peroxisomeproliferator-activated receptor (PPAR)-Ī“ agonist, which is produced mainly in the liver and plays a key role in the breakdown of fatty acids. It is almost similar in structure to Cardarine but GW0742 is 200 times more potent and has more health benefits.

How GW0742 Works

As a PPAR delta agonist, GW0742 enhances fatty acid metabolism. This in turn preserves blood sugar as well as physical endurance. It is because of this effect that athletes, bodybuilders, and other physically active individuals use this PPAR delta agonist. Even in very small doses, GW0742 can significantly boost energy levels and stamina.

Chemical Structure of GW0742

Research on GW0742

A. Promotes Muscle Regeneration and Increases Exercise Endurance

Studies suggest that GW0742 can help increase exercise endurance by promoting muscle regeneration:

    1. In a mouse model of muscle injury, GW0742 treatment resulted in faster skeletal muscle regeneration. [1]
    2. In trained mice, GW0742 treatment potentiated endurance and increased all running parameters. [2]
    3. In obese female mice, GW0742 increased endurance capacity by decreasing skeletal muscle inflammation. [3]
    4. In mice, GW0742 enhanced running endurance by 44%. [4]
    5. In mice, GW0742 induced an endurance-like oxidative muscle remodelling. [5-6]
    6. The injection of GW0742 in mice increased the formation of new blood vessels and heart muscle mass. [7]
    7. Studies reported that the pharmacological activation of PPARĪ²/Ī“ by GW0742 increases the formation of new blood vessels and enhances the production of muscle fibers. [8-10]

B. Helps Lose Weight

GW0742 is a selective PPARĪ“ (Peroxisome Proliferator-Activated Receptor Delta) agonist that has been studied for its potential metabolic benefits, including fat loss and improved energy expenditure. By activating PPARĪ“, GW0742 enhances fatty acid oxidation, increases endurance, and promotes lean muscle retention, making it appealing for individuals looking to lose weight while preserving muscle mass. Additionally, it may improve insulin sensitivity and reduce inflammation, both of which are crucial for effective weight management. While research is still ongoing, GW0742 shows promise as a compound that supports fat loss and metabolic health, particularly when combined with a proper diet and exercise regimen.

By breaking down fatty acids, GW0742 improves body composition and helps lose weight:

    1. In obese female mice, regular exercise together with GW0742 treatment effectively reduced visceral adipose tissue mass and skeletal muscle inflammation. [1]
    2. In mice, it was shown that GW0742 and phillyrin (an anti-obesity agent) have similar weight-reducing effects. [11]
    3. In obese mice, GW0742 administration resulted in a modest reduction in fat mass. [12]
    4. In obese mice, GW0742 exerted preventive effects against obesity. [13]
    5. In diet-induced obese mice, GW0742 therapy induced a decrease in fat mass. [14]
    6. The administration of GW0742 in obese mice resulted in decreased body weight and food intake. [15]
    7. In obese male mice, GW0742 treatment for 4 weeks reduced the formation of fat cells. [16]

C. Lowers the Risk of Heart Disease

GW0742, a potent PPAR-Ī“ agonist, has been studied for its potential cardiovascular benefits, particularly in reducing the risk of heart disease. By activating PPAR-Ī“, GW0742 enhances lipid metabolism, increases HDL (good cholesterol), and reduces LDL (bad cholesterol), which helps prevent atherosclerosis and arterial plaque buildup. Additionally, it improves endothelial function, reduces inflammation, and enhances mitochondrial efficiency in cardiac tissues, all of which contribute to better heart health. These effects collectively support improved circulation, reduced oxidative stress, and a lower risk of cardiovascular events such as heart attacks and strokes. While research is still ongoing, GW0742 shows promise as a therapeutic option for heart disease prevention and overall cardiovascular protection.

The ability of GW0742 to break down fatty acids produces beneficial effects on the heart, according to studies:

    1. In obese mice, GW0742 exerted protective effects against atherosclerosis (plaque formation within the heart arteries). [13]
    2. In rat heart tissue, GW0742 prevented heart enlargement due to high blood sugar levels by inhibiting free radicals. [17]
    3. A cell study found that GW0742 helps modulate signalling pathways associated with the growth of heart cells. [18]
    4. In mice, GW0742 administration had direct protective effects against right ventricular hypertrophy (enlargement of the right ventricles). [19]
    5. In rats with pulmonary hypertension, daily oral administration of GW0742 prevented heart enlargement and normalized right heart pressures. [20]
    6. In neonatal rats, GW0742 treatment enhanced lipid metabolism in the heart. [21]

D. Accelerates Wound Healing

GW0742, a selective PPAR-Ī“ agonist, has been shown to accelerate wound healing by promoting cellular regeneration, reducing inflammation, and enhancing angiogenesis. By activating PPAR-Ī“ pathways, GW0742 stimulates keratinocyte proliferation and migration, which are essential for skin repair. It also boosts collagen synthesis and fibroblast activity, strengthening the extracellular matrix and improving tissue integrity. Additionally, GW0742 enhances blood vessel formation, ensuring better oxygen and nutrient delivery to the wound site. Its anti-inflammatory properties help reduce excessive scarring and promote a more efficient healing process. These combined effects make GW0742 a promising candidate for improving wound healing, particularly in conditions where healing is impaired, such as diabetes or chronic ulcers.

The regenerative properties of GW0742 are also backed by a number of studies:

    1. In murine models, GW0742 regulated endothelial cell behaviour and improved tissue maintenance and repair. [22]
    2. In rats, GW0742 promoted wound healing by modulating inflammation. [23]

E. Boosts Brain Power

GW0742, a potent PPAR-Ī“ agonist, has been shown to boost brain power by enhancing cognitive function, protecting neurons, and promoting neuroplasticity. By activating PPAR-Ī“ pathways, GW0742 supports mitochondrial function and energy metabolism in brain cells, leading to improved focus, memory, and mental clarity. Its neuroprotective effects help reduce oxidative stress and inflammation, which are linked to neurodegenerative diseases like Alzheimer’s and Parkinson’s. Additionally, GW0742 may enhance synaptic plasticity and stimulate the growth of new neurons, contributing to long-term brain health. These benefits make GW0742 a promising compound for improving cognitive performance and potentially delaying age-related cognitive decline.

Evidence suggests that GW0742 is integral for brain health:

    1. In mice, GW0742 treatment alleviated cognitive dysfunction caused by radiation. [24]
    2. In mice, it was shown that PPARĪ“ activation alleviated brain toxicity induced by abnormal proteins known as beta amyloids. [25]
    3. A study reported that GW0742 plays an integral role in the maturation of brain cells. [26]
    4. In mice, GW0742 treatment successfully improved AD-related deficits by increasing fatty acid oxidation in astrocytes (cells in the central nervous system) and it also enhanced the cognition of the subjects. [27]
    5. In diabetic mice, oral administration with GW0742 for 2 weeks prevented deficits in spatial memory. [28]
    6. In rats exposed to global cerebral ischemia-reperfusion injury (insufficient blood flow to the brain), pretreatment with GW0742 exerted neuroprotective effects. [29]
    7. In mice, treatment with GW0742 significantly reduced cell death during a 12-hr exposure to low-KCl media. [30]
    8. In rats, GW0742 treated cognitive impairment due to insulin resistance and inflammation caused by high sugar intake. [31]
    9. In rats, GW0742 treatment prevented type 1 diabetes-induced cognitive impairment. [32]
    10. In mice, GW0742 treatment protected against brain dysfunction. [33]
    11. In a rodent model of Parkinson’s disease, injection with GW0742 exerted neuroprotective effects and prevented cognitive impairment. [34]
    12. In a mouse model of Alzheimer’s disease, oral treatment with GW0742 reduced abnormal brain proteins and proinflammatory mediators. [35]

F. Lowers Blood Pressure

GW0742, a selective PPAR-Ī“ agonist, has been shown to lower blood pressure by improving vascular function and reducing inflammation. By activating PPAR-Ī“ pathways, GW0742 enhances nitric oxide production, which promotes vasodilation and improves blood flow. This helps relax blood vessels, reducing resistance and lowering overall blood pressure levels. Additionally, GW0742 has been found to decrease oxidative stress and inflammation in the cardiovascular system, further supporting heart health. Its ability to enhance lipid metabolism and reduce arterial stiffness makes it a promising therapeutic candidate for managing hypertension and related cardiovascular conditions.

GW0742 can also lower blood pressure which can be beneficial for the treatment of hypertension:

    1. In rats, GW0742 exhibited blood pressure-lowering effects and protected the blood vessels against injury. [36]
    2. In spontaneously hypertensive rats (SHR), GW0742 exerted anti-hypertensive effects while promoting better blood vessel function. [37-38]

G. Improves Blood Sugar Levels and Treats Symptoms of Diabetes

GW0742, a potent PPAR-Ī“ agonist, has been shown to improve blood sugar levels and alleviate symptoms of diabetes by enhancing insulin sensitivity and glucose metabolism. By activating PPAR-Ī“, GW0742 promotes the uptake of glucose into muscle cells, reducing blood sugar spikes and improving overall glycemic control. Additionally, it helps regulate lipid metabolism, preventing the accumulation of excess fats that contribute to insulin resistance. Studies suggest that GW0742 also reduces inflammation and oxidative stress, two key factors in the progression of diabetes. These effects make GW0742 a promising candidate for managing diabetes and its complications, potentially offering an alternative approach to traditional treatments.

Studies show that GW0742 can help stabilize blood sugar levels and can be considered an anti-diabetic agent:

    1. In diabetic mice, GW0742 was able to improve blood sugar homeostasis (balance) and was found to be a good candidate for the development of anti-diabetic drugs in the future. [39]
    2. In diabetic rats, daily injection of GW0742 prevented complications caused by diabetes. [40]
    3. In diabetic mouse models, oral administration of GW0742 improved T2DM-induced memory impairments. [41]
    4. In rats, GW0742 was able to mediate dilation changes during a diabetic state. [42]
    5. In obese mice, GW0742 improved blood sugar metabolism and gene regulatory responses. [43]
    6. In rats, GW0742 treatment led to improved insulin signaling. [44]
    7. In diabetic mice, GW0742 treatment protected against diabetes-induced kidney complications. [45]
    8. In diabetic mice, GW0742 prevented nerve damage associated with the disease. [46]

H. Treats Lung Injuries

GW0742 has shown promising potential in treating lung injuries by reducing inflammation, oxidative stress, and tissue damage through activation of the PPAR-Ī“ pathway. This compound helps modulate immune responses in the lungs, limiting the production of pro-inflammatory cytokines that can worsen injury or lead to chronic conditions like fibrosis. In experimental models, GW0742 has been observed to improve oxygen exchange, preserve lung structure, and accelerate healing in damaged pulmonary tissues. These protective effects make it a compelling therapeutic candidate for conditions such as acute lung injury (ALI), acute respiratory distress syndrome (ARDS), and other inflammatory lung diseases.

A good deal of evidence shows that GW0742 can help protect the lungs against various forms of injury:

    1. In rats, daily oral treatment with GW0742 (30 mg/kg) for 3 weeks significantly reduced the increased pressure within the blood vessels of the lungs. [20]
    2. In mice, GW0742 prevented acute lung injuries and complications. [47]
    3. In a mouse model of emphysema (damage to the air sacs in the lungs), GW0742 repaired the collapsed alveoli. [48]
    4. In rats with lung injury caused by exposure to high levels of oxygen, GW0742 treatment prevented further lung damage. [49]
    5. The administration of GW0742 in mice reduced lung inflammation induced by bleomycin instillation. [50]

I. Improves Eye Health

GW0742 may improve eye health by activating PPAR-Ī“ receptors, which play a role in reducing inflammation and protecting retinal cells from oxidative stress. This action can help preserve vision and may offer therapeutic benefits in conditions like diabetic retinopathy and age-related macular degeneration. While more human studies are needed, early research suggests that GW0742 supports ocular health by enhancing cellular energy metabolism and reducing damage to eye tissues.

The activation of PPARĪ²/Ī“ by GW0742 produces beneficial effects on visual function, according to studies:

    1. The activation of PPARĪ²/Ī“ appears to lower the risk of age-related macular degeneration (AMD). [51]
    2. In rats with oxygen-induced retinal damage, GW0742 promoted healing of the eye tissues. [52]

Associated Side Effects of GW0742

GW0742 side effects are very uncommon. There have been some side effects associated with the use of this drug wherein the patient had one of the issues listed below at some point while being on GW0742. However, these side effects werenā€™t confirmed to be associated with the treatment and could have been a coincidence and not related to the use of GW0742. Despite this, it was listed as a side effect associated with GW0742 even though these associated side effects are very uncommon.

Side effects associated with GW0742 may include the following:

  • Increased heart size
  • Increased levels of calcineurin, a cellular enzyme that activates the T cells of the immune system

GW0742 vs GW50156

GW0742 and GW501516 (commonly known as Cardarine) are both PPAR-Ī“ agonists, but they have distinct characteristics and applications. GW501516 is well-known for its ability to enhance endurance, fat metabolism, and cardiovascular performance, making it popular among athletes and bodybuilders. It primarily stimulates fatty acid oxidation and mitochondrial biogenesis, leading to improved energy efficiency and increased stamina. However, concerns about potential carcinogenic effects in animal studies have raised safety questions regarding long-term use.

On the other hand, GW0742 is a more selective and potent PPAR-Ī“ agonist, with additional benefits beyond endurance and fat metabolism. It has been studied for its potential role in improving cardiovascular health, lowering blood pressure, and reducing inflammation, making it a promising candidate for treating metabolic disorders and chronic inflammatory diseases. GW0742 also appears to have neuroprotective and wound-healing properties, which distinguish it from GW501516.

While both compounds share similar mechanisms of action, GW0742 is considered to have a broader therapeutic scope with potential medical applications, whereas GW501516 is primarily used for performance enhancement. The safety profile of GW0742 is still under investigation, but its effects on cardiovascular and metabolic health may make it a more viable option for clinical use in the future.

GW0742 Dosage

The optimal dosage of GW0742 is not well-established for human use, as most studies have been conducted in animal models. In research settings, doses typically range from 1 to 10 mg/kg per day, depending on the specific condition being studied. However, due to its high potency as a PPAR-Ī“ agonist, lower doses may still provide significant metabolic and anti-inflammatory benefits.

Since GW0742 is not approved for human consumption, there are no standardized dosage guidelines. Users who experiment with GW0742 often start with lower doses, around 2-5 mg per day, to assess tolerance and potential effects. Higher doses may amplify benefits such as improved endurance, cardiovascular health, and fat metabolism, but they could also increase the risk of adverse effects.

Long-term safety data on GW0742 are limited, so careful monitoring of health markers is essential when using it. As with any research compound, it is crucial to consult healthcare professionals before experimenting with GW0742, especially for individuals with pre-existing medical conditions or those using other medications.

GW0742 Bodybuilding

GW0742 has gained attention in the bodybuilding community due to its potential to enhance endurance, fat metabolism, and muscle recovery. As a potent PPAR-Ī“ agonist, it activates pathways that promote energy expenditure and reduce inflammation, making it appealing for athletes looking to improve overall performance. Its effects are often compared to GW501516 (Cardarine), though GW0742 is believed to have a stronger affinity for PPAR-Ī“ receptors.

One of the key benefits of GW0742 in bodybuilding is its ability to increase fatty acid oxidation, which can help users achieve a leaner physique while maintaining muscle mass. Additionally, its anti-inflammatory properties may support faster recovery, reducing muscle soreness and allowing for more intense training sessions. Some research also suggests that it can improve cardiovascular function, which is essential for endurance athletes and bodybuilders who engage in high-intensity workouts.

Despite its promising effects, GW0742 remains an experimental compound with limited human studies. Bodybuilders considering its use should be aware of potential risks, including unknown long-term side effects. Since it is not approved for human consumption, responsible use, proper dosing, and post-cycle health monitoring are crucial to minimizing risks while maximizing benefits.

GW0742 Half Life

GW0742, a potent PPAR-Ī“ agonist, is known for its relatively short half-life compared to some other compounds in its class. The estimated half-life of GW0742 is typically between 4 to 6 hours, meaning it is metabolized and cleared from the body relatively quickly. Because of this short duration, maintaining consistent plasma levels may require more frequent dosing or sustained-release formulations for therapeutic applications.

The half-life of GW0742 directly impacts how it is administered in both research and potential clinical settings. Frequent dosing may be necessary to ensure that the compound maintains its effects on metabolic regulation, inflammation reduction, or cardiovascular support throughout the day. This is especially important in experimental models where the timing and consistency of exposure influence results.

While the short half-life can be a limitation, it may also offer advantages, such as more precise control over the duration of its effects and potentially reduced risk of long-term accumulation or side effects. Researchers are exploring ways to optimize dosing strategies to maximize GW0742ā€™s therapeutic potential while balancing safety and efficacy.

GW0742 Cycle

A typical GW0742 cycle for research purposes usually spans between 4 to 8 weeks, depending on the desired outcomes and the specific goals of the study. Researchers often administer the compound daily due to its short half-life, ensuring consistent activation of PPAR-Ī“ receptors throughout the cycle. Dosages are carefully measured, commonly ranging from 2 to 10 mg per day in animal models, although exact amounts vary based on body weight and experimental design.

During the GW0742 cycle, researchers may observe enhanced endurance, improved glucose metabolism, reduced inflammation, and potential fat oxidation effects. These outcomes are often monitored using biomarkers, performance tests, or imaging studies. Since GW0742 is non-steroidal, it does not typically require post-cycle therapy (PCT), but researchers still assess for hormonal or metabolic changes during and after the cycle to ensure safety.

At the end of a GW0742 cycle, itā€™s important to evaluate recovery and long-term effects. Researchers often implement a washout period to allow the compound to clear from the system, monitoring for any residual effects or changes in physiological markers. This helps in understanding the full impact of GW0742 and optimizing future cycles for therapeutic or performance-based applications.

GW 0742 Side Effects

GW0742, while promising in preclinical research, has shown potential side effects that researchers closely monitor. One of the primary concerns is gastrointestinal discomfort, which may include nausea or mild cramping in some test subjects. These effects are generally dose-dependent and tend to lessen when lower dosages are used or when administered with food.

Another possible side effect observed in some studies is altered liver enzyme levels, indicating that GW0742 might exert some hepatic stress over extended use. Although itā€™s not classified as hepatotoxic, regular liver function monitoring is recommended during research cycles, especially in long-term studies. Additionally, changes in lipid profiles, such as reduced HDL cholesterol, have also been noted.

Lastly, as GW0742 is a potent PPAR-Ī“ agonist, it can impact gene expression related to metabolism, inflammation, and cell growth. While this modulation is often the basis for its therapeutic potential, it may also carry unintended effects like hormonal imbalances or metabolic shifts if not carefully managed. More human research is needed to fully understand the long-term safety and side effect profile of GW074.

GW0742 Uses

GW0742 is primarily used in scientific research to explore its role as a selective PPAR-Ī“ (peroxisome proliferator-activated receptor delta) agonist. This compound has shown potential in regulating lipid metabolism, enhancing endurance, and improving energy utilization, making it a promising candidate for studies on metabolic disorders and cardiovascular health. Researchers use GW0742 to understand how PPAR-Ī“ activation can influence fat burning and energy balance at the cellular level.

Another key use of GW0742 is in studies related to inflammation and immune response. Its anti-inflammatory properties have made it valuable in preclinical models of conditions like atherosclerosis, lung injury, and kidney inflammation. By targeting PPAR-Ī“, GW0742 helps modulate cytokine production and reduce oxidative stress, which are critical components in chronic inflammatory diseases.

GW0742 is also being explored for its potential benefits in treating diabetes and improving insulin sensitivity. Research indicates that it may help regulate blood glucose levels and improve lipid profiles in diabetic models. This has sparked interest in its use as a potential therapeutic for type 2 diabetes and metabolic syndrome, although further studies are needed to fully understand its safety and efficacy in humans.

Share This Page

FAQ

What does GW0742 do?

This study shows that activation of PPAR-Ī²/Ī“ promotes, while its inhibition reduces, preretinal neovascularization (NV) in models of ocular disease. In human retinal endothelial cells, the PPAR-Ī²/Ī“ agonist GW0742ā€”a selective small molecule agonistā€”increased Angptl4 expression and enhanced tube formation, while the antagonist GSK0660 suppressed both proliferation and tube formation. In a rat model of oxygen-induced retinopathy, GW0742 elevated retinal Angptl4 levels and worsened NV, whereas GSK0660 significantly reduced NV. It activates the PPAR-Ī“ receptor, influencing metabolism and inflammation. These findings suggest that PPAR-Ī²/Ī“ contributes to pathological ocular NV and that its inhibition may offer a novel therapeutic strategy.

What is GW0742 used for?

Itā€™s used in research to study metabolic diseases, cardiovascular health, and inflammation, with growing interest in its role in hepatic metabolism.

How long does GW0742 stay in your system?

Its effects may last up to 24 hours, but human data is limited for this selective peroxisome proliferator.

What are the results of GW0742?

Studies show improved lipid metabolism, reduced inflammation, and better endurance, which may be linked to its chemical structure.

What is the mechanism of action of GW0742?

It selectively activates the PPAR-Ī“ receptor to regulate gene expression related to energy use and can also influence insulin levels.

What is the other name for GW0742?

Itā€™s also known as GSK3787 in some research contexts and has been shown to interact with key enzymes involved in metabolic regulation.

What is the half-life of injectable cardarine?

Injectable cardarine has an estimated half-life of about 20 to 24 hours, maintaining biological activity throughout that period.

What does GW0742 mean?

Itā€™s a research chemical name assigned to a synthetic PPAR-Ī“ agonist that influences the expression of target genes involved in energy regulation and lipid metabolism. Scientists study its modulation of target genes to explore potential therapeutic applications.

What are the effects of GW0742?

Potential effects include enhanced fat burning, reduced inflammation, and improved endurance.

What does GW0742 do?

It modulates energy metabolism and inflammatory pathways through PPAR-Ī“ activation.

What is the use of GW0742?

Its primary use is in preclinical research for treating metabolic and inflammatory conditions.

Reference

  1. Le Garf S, Murdaca J, Mothe-Satney I, et al. Complementary Immunometabolic Effects of Exercise and PPARĪ²/Ī“ Agonist in the Context of Diet-Induced Weight Loss in Obese Female Mice. Int J Mol Sci. 2019;20(20):5182. Published 2019 Oct 19. doi:10.3390/ijms20205182.

  2. Mothe-Satney I, Piquet J, Murdaca J, Sibille B, Grimaldi PA, Neels JG, Rousseau AS. PeroxisomeProliferator Activated Receptor Beta (PPARĪ²) activity increases the immune response and shortens the early phases of skeletal muscle regeneration. Biochimie. 2017 May;136:33-41. doi: 10.1016/j.biochi.2016.12.001. Epub 2016 Dec 7. PMID: 27939528.

  3. Manio MC, Inoue K, Fujitani M, Matsumura S, Fushiki T. Combined pharmacological activation of AMPK and PPARĪ“ potentiates the effects of exercise in trained mice. Physiol Rep. 2016 Mar;4(5):e12625. doi: 10.14814/phy2.12625. PMID: 26997622; PMCID: PMC4823600.

  4. Narkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E, Mihaylova MM, Nelson MC, Zou Y, Juguilon H, Kang H, Shaw RJ, Evans RM. AMPK and PPARdeltaagonists are exercise mimetics. Cell. 2008 Aug 8;134(3):405-15. doi: 10.1016/j.cell.2008.06.051. Epub 2008 Jul 31. PMID: 18674809; PMCID: PMC2706130.

  5. GaudelC , Schwartz C , Giordano C ,AbumradNA , Grimaldi P. 2008. Pharmacological activation of PPARĪ² promotes rapid and calcineurin-dependent fiber remodeling and angiogenesis in mouse skeletal muscle. Am J Physiol Endocrinol Metab295:E297ā€“E304.

  6. Giordano C , Rousseau AS , Wagner N ,GaudelC ,MurdacaJ , Jehl-PiĆ©triC , Sibille B , Grimaldi PA , Lopez P. 2009. Peroxisome proliferator-activated receptor Ī² activation promotes myonuclear accretion in skeletal muscle of adult and aged mice. Pflugers Arch 458:901ā€“913.

  7. Wagner, N., Jehl-PiĆ©tri, C., Lopez, P., Murdaca, J., Giordano, C., Schwartz, C., Gounon, P., Hatem, S. N., Grimaldi, P., & Wagner, K. D. (2009). Peroxisome proliferator-activated receptor beta stimulation induces rapid cardiac growth and angiogenesis via direct activation of calcineurin. Cardiovascular research, 83(1), 61ā€“71. https://doi.org/10.1093/cvr/cvp106.

  8. Allen, D. M., Chen, L. E., Seaber, A. V., & Urbaniak, J. R. (1995). Pathophysiology and related studies of the no reflow phenomenon in skeletal muscle. Clinical orthopaedics and related research, (314), 122ā€“133.

  9. Roy, R. R., Monke, S. R., Allen, D. L., & Edgerton, V. R. (1999). Modulation of myonuclear number in functionally overloaded and exercised rat plantaris fibers. Journal of applied physiology (Bethesda, Md. : 1985), 87(2), 634ā€“642. https://doi.org/10.1152/jappl.1999.87.2.634.

  10. Li, P., Akimoto, T., Zhang, M., Williams, R. S., & Yan, Z. (2006). Resident stem cells are not required for exercise-induced fiber-type switching and angiogenesis but are necessary for activity-dependent muscle growth. American journal of physiology. Cell physiology, 290(6), C1461ā€“C1468. https://doi.org/10.1152/ajpcell.00532.2005.

  11. Xiao HB, Sui GG, Lu XY. Phillyrin lowers body weight in obese mice via the modulation of PPAR/-ANGPTL 4 pathway. Obes Res Clin Pract. 2018 Jan-Feb;12(Suppl 2):71-79. doi: 10.1016/j.orcp.2017.02.002. Epub 2017 Mar 17. PMID: 28320596.

  12. Harrington WW, S Britt C, G Wilson J, et al. The Effect of PPARalpha, PPARdelta, PPARgamma, and PPARpan Agonists on Body Weight, Body Mass, and Serum Lipid Profiles in Diet-Induced Obese AKR/J Mice. PPAR Res. 2007;2007:97125. doi:10.1155/2007/97125.

  13. Toral M, GĆ³mez-GuzmĆ”n M, JimĆ©nez R, Romero M, Zarzuelo MJ, Utrilla MP, Hermenegildo C, Cogolludo Ɓ, PĆ©rez-VizcaĆ­no F, GĆ”lvez J, Duarte J. Chronic peroxisomeproliferator-activated receptorĪ²/Ī“ agonist GW0742 prevents hypertension, vascular inflammatory and oxidative status, and endothelial dysfunction in diet-induced obesity. J Hypertens. 2015 Sep;33(9):1831-44. doi: 10.1097/HJH.0000000000000634. PMID: 26147382.

  14. Harrington WW, S Britt C, G Wilson J, et al. The Effect of PPARalpha, PPARdelta, PPARgamma, and PPARpan Agonists on Body Weight, Body Mass, and Serum Lipid Profiles in Diet-Induced Obese AKR/J Mice. PPAR Res. 2007;2007:97125. doi:10.1155/2007/97125.

  15. Harrington, W. W., S Britt, C., G Wilson, J., O Milliken, N., G Binz, J., C Lobe, D., R Oliver, W., C Lewis, M., & M Ignar, D. (2007). The Effect of PPARalpha, PPARdelta, PPARgamma, and PPARpan Agonists on Body Weight, Body Mass, and Serum Lipid Profiles in Diet-Induced Obese AKR/J Mice. PPAR research, 2007, 97125. https://doi.org/10.1155/2007/97125.

  16. Rachid, T. L., Silva-Veiga, F. M., Graus-Nunes, F., Bringhenti, I., Mandarim-de-Lacerda, C. A., & Souza-Mello, V. (2018). Differential actions of PPAR-Ī± and PPAR-Ī²/Ī“ on beige adipocyte formation: A study in the subcutaneous white adipose tissue of obese male mice. PloS one, 13(1), e0191365. https://doi.org/10.1371/journal.pone.0191365.

  17. Cheng KC, Chang WT, Li Y, Cheng YZ, Cheng JT, Chen ZC. GW0742 activates peroxisomeproliferator-activated receptor Ī“ to reduce free radicals and alleviate cardiac hypertrophy induced by hyperglycemia in cultured H9c2 cells. J Cell Biochem. 2018 Nov;119(11):9532-9542. doi: 10.1002/jcb.27270. Epub 2018 Aug 20. PMID: 30129179.

  18. Galatou E, Kelly T, Lazou A. The PPARĪ²/Ī“ agonist GW0742 modulates signaling pathways associated with cardiac myocyte growth via a non-genomic redox mechanism. Mol Cell Biochem. 2014 Oct;395(1-2):145-54. doi: 10.1007/s11010-014-2120-5. Epub 2014 Jun 18. PMID: 24939361.

  19. Kojonazarov B, Luitel H, Sydykov A, et al. The peroxisome proliferator-activated receptor Ī²/Ī“ agonist GW0742 has direct protective effects on right heart hypertrophy [published correction appears in Pulm Circ. 2014 Jun;4(2):352]. Pulm Circ. 2013;3(4):926-935. doi:10.1086/674755.

  20. Harrington LS, Moreno L, Reed A, et al. The PPARbeta/delta agonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension. PLoS One. 2010;5(3):e9526. Published 2010 Mar 4. doi:10.1371/journal.pone.0009526.

  21. Kuo, S. C., Ku, P. M., Chen, L. J., Niu, H. S., & Cheng, J. T. (2013). Activation of receptors Ī“ (PPARĪ“) by agonist (GW0742) may enhance lipid metabolism in heart both in vivo and in vitro. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 45(12), 880ā€“886. https://doi.org/10.1055/s-0033-1348317.

  22. Romero M, Toral M, Robles-Vera I, SĆ”nchez M, JimĆ©nez R, O’Valle F, Rodriguez-Nogales A, PĆ©rez-Vizcaino F, GĆ”lvez J, Duarte J. Activation of PeroxisomeProliferator Activator Receptor Ī²/Ī“ Improves Endothelial Dysfunction and Protects Kidney in Murine Lupus. Hypertension. 2017 Apr;69(4):641-650. doi: 10.1161/HYPERTENSIONAHA.116.08655. Epub 2017 Feb 27. PMID: 28242713.

  23. Yue TL, Nerurkar SS, Bao W, Jucker BM, Sarov-Blat L, Steplewski K, Ohlstein EH, Willette RN. In vivo activation of peroxisomeproliferator-activated receptor-delta protects the heart from ischemia/reperfusion injury in Zucker fatty rats. J Pharmacol Exp Ther. 2008 May;325(2):466-74. doi: 10.1124/jpet.107.135327. Epub 2008 Feb 20. PMID: 18287212.

  24. Schnegg, C. I., Greene-Schloesser, D., Kooshki, M., Payne, V. S., Hsu, F. C., & Robbins, M. E. (2013). The PPARĪ“ agonist GW0742 inhibits neuroinflammation, but does not restore neurogenesis or prevent early delayed hippocampal-dependent cognitive impairment after whole-brain irradiation. Free radical biology & medicine, 61, 1ā€“9. https://doi.org/10.1016/j.freeradbiomed.2013.03.002.

  25. An YQ, Zhang CT, Du Y, Zhang M, Tang SS, Hu M, Long Y, Sun HB, Hong H. PPARĪ“ agonist GW0742 ameliorates AĪ²1-42-induced hippocampal neurotoxicity in mice. Metab Brain Dis. 2016 Jun;31(3):663-71. doi: 10.1007/s11011-016-9800-7. Epub 2016 Feb 11. PMID: 26864581.

  26. Benedetti E, Di Loreto S, D’Angelo B, Cristiano L, d’Angelo M, Antonosante A, Fidoamore A, Golini R, Cinque B, Cifone MG, Ippoliti R, Giordano A, Cimini A. The PPARĪ²/Ī“ Agonist GW0742 Induces Early Neuronal Maturation of Cortical Post-Mitotic Neurons: Role of PPARĪ²/Ī“ in Neuronal Maturation. J Cell Physiol. 2016 Mar;231(3):597-606. doi: 10.1002/jcp.25103. PMID: 26206209.

  27. Konttinen H, Gureviciene I, Oksanen M, Grubman A, Loppi S, Huuskonen MT, Korhonen P, Lampinen R, Keuters M, Belaya I, Tanila H, Kanninen KM, Goldsteins G, Landreth G, Koistinaho J, Malm T. PPARĪ²/Ī“-agonist GW0742 ameliorates dysfunction in fatty acid oxidation in PSEN1Ī”E9 astrocytes. Glia. 2019 Jan;67(1):146-159. doi: 10.1002/glia.23534. Epub 2018 Nov 19. PMID: 30453390; PMCID: PMC7526864.

  28. Abdel-Rahman EA, Bhattacharya S, Buabeid M, Majrashi M, Bloemer J, Tao YX, Dhanasekaran M, Escobar M, Amin R, Suppiramaniam V. PPAR-Ī“ Activation Ameliorates Diabetes-Induced Cognitive Dysfunction by Modulating Integrin-linked Kinase and AMPA Receptor Function. J Am CollNutr. 2019 Nov-Dec;38(8):693-702. doi: 10.1080/07315724.2019.1598307. Epub 2019 Apr 22. PMID: 31008686.

  29. Kuang G, He Q, Zhang Y, Zhuang R, Xiang A, Jiang Q, Luo Y, Yang J. Modulation of Preactivation of PPAR-Ī² on Memory and Learning Dysfunction and Inflammatory Response in the Hippocampus in Rats Exposed to Global Cerebral Ischemia/Reperfusion. PPAR Res. 2012;2012:209794. doi: 10.1155/2012/209794. Epub 2012 Sep 27. PMID: 23056034; PMCID: PMC3465902.

  30. Smith SA, Monteith GR, Robinson JA, Venkata NG, May FJ, Roberts-Thomson SJ. Effect of the peroxisomeproliferator-activated receptor beta activator GW0742 in rat cultured cerebellar granule neurons. J Neurosci Res. 2004 Jul 15;77(2):240-9. doi: 10.1002/jnr.20153. PMID: 15211590.

  31. Benetti, E., Mastrocola, R., Rogazzo, M., Chiazza, F., Aragno, M., Fantozzi, R., Collino, M., & Minetto, M. A. (2013). High sugar intake and development of skeletal muscle insulin resistance and inflammation in mice: a protective role for PPAR- Ī“ agonism. Mediators of inflammation, 2013, 509502. https://doi.org/10.1155/2013/509502.

  32. Quintela, A. M., JimĆ©nez, R., GĆ³mez-GuzmĆ”n, M., Zarzuelo, M. J., Galindo, P., SĆ”nchez, M., Vargas, F., Cogolludo, A., Tamargo, J., PĆ©rez-VizcaĆ­no, F., & Duarte, J. (2012). Activation of peroxisome proliferator-activated receptor-Ī²/-Ī“ (PPARĪ²/Ī“) prevents endothelial dysfunction in type 1 diabetic rats. Free radical biology & medicine, 53(4), 730ā€“741. https://doi.org/10.1016/j.freeradbiomed.2012.05.045.

  33. Tian XY, Wong WT, Wang N, et al. PPARĪ“ activation protects endothelial function in diabetic mice. Diabetes. 2012;61(12):3285-3293. doi:10.2337/db12-0117.

  34. Das, N. R., Gangwal, R. P., Damre, M. V., Sangamwar, A. T., & Sharma, S. S. (2014). A PPAR-Ī²/Ī“ agonist is neuroprotective and decreases cognitive impairment in a rodent model of Parkinson’s disease. Current neurovascular research, 11(2), 114ā€“124. https://doi.org/10.2174/1567202611666140318114037.

  35. Malm, T., Mariani, M., Donovan, L. J., Neilson, L., & Landreth, G. E. (2015). Activation of the nuclear receptor PPARĪ“ is neuroprotective in a transgenic mouse model of Alzheimer’s disease through inhibition of inflammation. Journal of neuroinflammation, 12, 7. https://doi.org/10.1186/s12974-014-0229-9.

  36. Romero M, JimĆ©nez R, Toral M, LeĆ³n-GĆ³mez E, GĆ³mez-GĆŗzman M, SĆ”nchez M, Zarzuelo MJ, RodrĆ­guez-GĆ³mez I, Rath G, Tamargo J, PĆ©rez-VizcaĆ­no F, Dessy C, Duarte J. Vascular and Central Activation of PeroxisomeProliferator-Activated Receptor-Ī² Attenuates Angiotensin II-Induced Hypertension: Role of RGS-5. J Pharmacol Exp Ther. 2016 Jul;358(1):151-63. doi: 10.1124/jpet.116.233106. Epub 2016 Apr 27. PMID: 27189971.

  37. MarĆ­a JosĆ© Zarzuelo, Manuel GĆ³mez-GuzmĆ”n, Rosario JimĆ©nez, Ana MarĆ­a Quintela, Miguel Romero, Manuel SĆ”nchez, Antonio Zarzuelo, Juan Tamargo, Francisco PĆ©rez-VizcaĆ­no, Juan Duarte, Effects of peroxisome proliferator-activated receptor-Ī² activation in endothelin-dependent hypertension, Cardiovascular Research, Volume 99, Issue 4, 1 September 2013, Pages 622ā€“631, https://doi.org/10.1093/cvr/cvt152.

  38. Zarzuelo MJ, JimĆ©nez R, Galindo P, SĆ”nchez M, Nieto A, Romero M, Quintela AM, LĆ³pez-SepĆŗlveda R, GĆ³mez-GuzmĆ”n M, BailĆ³n E, RodrĆ­guez-GĆ³mez I, Zarzuelo A, GĆ”lvez J, Tamargo J, PĆ©rez-VizcaĆ­no F, Duarte J. Antihypertensive effects of peroxisome proliferator-activated receptor-Ī² activation in spontaneously hypertensive rats. Hypertension. 2011 Oct;58(4):733-43. doi: 10.1161/HYPERTENSIONAHA.111.174490. Epub 2011 Aug 8. PMID: 21825230.

  39. Niu HS, Ku PM, Niu CS, Cheng JT, Lee KS. Development of PPAR-agonist GW0742 as antidiabetic drug: study in animals. Drug Des DevelTher. 2015 Oct 14;9:5625-32. doi: 10.2147/DDDT.S95045. PMID: 26508837; PMCID: PMC4610778.

  40. Khazaei M, Salehi E, Rashidi B, Javanmard SH, Fallahzadeh AR. Role of peroxisomeproliferator-activated receptor Ī² agonist on angiogenesis in hindlimb ischemic diabetic rats. J Diabetes Complications. 2012 Mar-Apr;26(2):137-40. doi: 10.1016/j.jdiacomp.2012.02.005. Epub 2012 Mar 29. PMID: 22464549.

  41. Abdel-Rahman EA, Bhattacharya S, Buabeid M, Majrashi M, Bloemer J, Tao YX, Dhanasekaran M, Escobar M, Amin R, Suppiramaniam V. PPAR-Ī“ Activation Ameliorates Diabetes-Induced Cognitive Dysfunction by Modulating Integrin-linked Kinase and AMPA Receptor Function. J Am CollNutr. 2019 Nov-Dec;38(8):693-702. doi: 10.1080/07315724.2019.1598307. Epub 2019 Apr 22. PMID: 31008686.

  42. Perez-Diaz N, Pushkarsky I, Oweis N, Lione LA, Mackenzie LS. The Non-Genomic Effects of the PPARĪ²Ī³ Agonist GW0742 on Streptozotocin Treated Rat Aorta. Curr Mol Pharmacol. 2018;11(2):149-154. doi: 10.2174/1874467209666161229124356. PMID: 28034288.

  43. KrƤmer DK, Al-Khalili L, Perrini S, Skogsberg J, Wretenberg P, Kannisto K, Wallberg-Henriksson H, Ehrenborg E, Zierath JR, Krook A. Direct activation of glucose transport in primary human myotubes after activation of peroxisomeproliferator-activated receptor delta. Diabetes. 2005 Apr;54(4):1157-63. doi: 10.2337/diabetes.54.4.1157. PMID: 15793256.

  44. Lee MY, Choi R, Kim HM, Cho EJ, Kim BH, Choi YS, Naowaboot J, Lee EY, Yang YC, Shin JY, Shin YG, Chung CH. Peroxisomeproliferator-activated receptor Ī“ agonist attenuates hepatic steatosis by anti-inflammatory mechanism. Exp Mol Med. 2012 Oct 31;44(10):578-85. doi: 10.3858/emm.2012.44.10.066. PMID: 22824914; PMCID: PMC3490079.

  45. Matsushita Y, Ogawa D, Wada J, et al. Activation of peroxisomeproliferator-activated receptor delta inhibits streptozotocin-induced diabetic nephropathy through anti-inflammatory mechanisms in mice. Diabetes. 2011;60(3):960-968. doi:10.2337/db10-1361.

  46. Yuichi Matsushita, Daisuke Ogawa, Jun Wada, Noriko Yamamoto, Kenichi Shikata, Chikage Sato, Hiromi Tachibana, Noriko Toyota, Hirofumi MakinoDiabetes Mar 2011, 60 (3) 960-968; DOI: 10.2337/db10-136.

  47. Di Paola R, Crisafulli C, Mazzon E, Esposito E, Paterniti I, Galuppo M, Genovese T, Thiemermann C, Cuzzocrea S. GW0742, a high-affinity PPAR -beta/delta agonist, inhibits acute lung injury in mice. Shock. 2010 Apr;33(4):426-35. doi: 10.1097/SHK.0b013e3181b8f2fb. PMID: 20407409.

  48. Ozawa C, Horiguchi M, Akita T, Oiso Y, Abe K, Motomura T, Yamashita C. Pulmonary Administration of GW0742, a High-Affinity PeroxisomeProliferator-Activated Receptor Agonist, Repairs Collapsed Alveoli in an Elastase-Induced Mouse Model of Emphysema. BiolPharm Bull. 2016;39(5):778-85. doi: 10.1248/bpb.b15-00909. PMID: 27150147.

  49. Bao, X. C., Fang, Y. Q., You, P., Zhang, S., & Ma, J. (2014). Protective role of peroxisome proliferator-activated receptor-Ī²/Ī“ against pulmonary oxygen toxicity mediated through changes in NOS expression levels. Experimental lung research, 40(3), 105ā€“116. https://doi.org/10.3109/01902148.2013.879497.

  50. Galuppo M, Di Paola R, Mazzon E, Esposito E, Paterniti I, Kapoor A, Thiemermann C, Cuzzocrea S. GW0742, a high affinity PPAR-Ī²/Ī“ agonist reduces lung inflammation induced by bleomycin instillation in mice. Int J ImmunopatholPharmacol. 2010 Oct-Dec;23(4):1033-46. doi: 10.1177/039463201002300408. PMID: 21244753.

  51. Choudhary M, Ding JD, Qi X, Boulton ME, Yao PL, Peters JM, Malek G. PPARĪ²/Ī“ selectively regulates phenotypic features of age-related macular degeneration. Aging (Albany NY). 2016 Sep 8;8(9):1952-1978. doi: 10.18632/aging.101031. PMID: 27622388; PMCID: PMC5076447.

  52. Capozzi ME, McCollum GW, Savage SR, Penn JS. Peroxisomeproliferator-activated receptor-Ī²/Ī“ regulates angiogenic cell behaviors and oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2013;54(6):4197-4207. Published 2013 Jun 19. doi:10.1167/iovs.13-11608.

Other Peptides

Melanotan 1

Valproic Acid

BPC-157

Noopept

Aminophylline

Success Stories

men testimonial before after

At the age of 60, I look and feel better than I ever have in my entire life! Switching my health program and hormone replacement therapy regimen over to Genemedics was one of the best decisions Iā€™ve ever made in my life! Genemedics and Dr George have significantly improved my quality of life and also dramatically improved my overall health. I hav...
Nick Cassavetes ,60 yrs old Movie Director (ā€œThe Notebookā€, ā€œJohn Qā€, ā€œAlpha Dogā€), Actor and Writer

See All Menā€™s Testimonials

Call 800-277-4041 for a Free Consultation

What to expect during your consultation:
  • Usually takes 15-30 minutes
  • Completely confidential
  • No obligation to purchase anything
  • We will discuss your symptoms along with your health and fitness goals
  • Free post-consult access for any additional questions you may have

About

GenemedicsĀ® Health Institute is a global premier institute dedicated to revolutionizing health and medicine through healthy lifestyle education, guidance and accountability in harmony with functional medicine. Our physician-supervised health programs are personally customized to help you reach your health and fitness goals while looking and feeling better than ever.

Quick Links

Our Services

Ā Our Locations

genemedics logo

280 North Old Woodward Ave. Suite 210 Birmingham MI 48009,USA

800-277-4041

info@genemedics.com

© Copyright Genemedics Health Institute. All Rights Reserved. Privacy Policy.

Back to Top
-

Free Consultation

STEPS AWAY FROM A YOUNGER. HEALTHIER YOU!

Call 800-277-4041 for a Free Consultation

What to expect during your consultation:

  • Usually takes 15-30 minutes
  • Completely confidential
  • No obligation to purchase anything
  • We will discuss your symptoms along with your health and fitness goals
  • Free post-consult access for any additional questions you may have
Captch Background